Get started
Author

Aleksandra Wieczorek

Observed names: A Wieczorek, A. Wieczorek, A. Wieczorek, Wieczorek, Aleksandra
ORCID: 0000-0001-6750-2628
Observed ORCID: 0000-0001-6750-2628
OpenAlex ID: A5036855099
Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study
2018 · Daniel A. Morgenstern, Ulrike Pötschger, et al. · Pediatric Blood & Cancer · 73
Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance
2021 · Giuseppe Barone, Ailish Barry, et al. · Pediatric Drugs · 48
Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience
2020 · P. Berlanga, C. Pasqualini, et al. · European Journal of Cancer · 30
PDF
Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
2023 · Aleksandra Wieczorek, Anna Zaniewska-Tekieli, et al. · Frontiers in Oncology · 29
PDF
Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate
2020 · Magdalena Cwiklinska, Malgorzata Czogala, et al. · Frontiers in Pediatrics · 28
PDF
The Role of Surrogate Endpoints in the Evaluation of Efficacy and Safety of Therapeutic Interventions in Diabetes Mellitus
2008 · Aleksandra Wieczorek, Przemyslaw Rys, et al. · The Review of Diabetic Studies · 28
PDF
Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
2022 · Aleksandra Wieczorek, Carla Manzitti, et al. · Cancers · 24
Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial.
2019 · Holger N. Lode, Dominique Valteau-Couanet, et al. · Journal of Clinical Oncology · 23
Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia
2022 · Katarzyna Pawinska-Wasikowska, Aleksandra Wieczorek, et al. · Cancers · 20
The role of N-Myc gene amplification in neuroblastoma childhood tumour – single-centre experience
2018 · Przemysław Kaczówka, Aleksandra Wieczorek, et al. · Współczesna Onkologia · 20
PDF
Efficacy and Safety of Anti-GD2 Immunotherapy with Dinutuximab Beta in the Treatment of Relapsed/Refractory High-Risk Neuroblastoma
2025 · Aleksandra Wieczorek, Katarzyna Śladowska, et al. · Targeted Oncology · 18
PDF
Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain
2019 · Katarzyna Szewczyk, Aleksandra Wieczorek, et al. · Frontiers in Oncology · 18
PDF
Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data
2023 · Aleksandra Wieczorek, Urszula Żebrowska, et al. · Journal of Clinical Medicine · 17
PDF
Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review
2024 · Urszula Żebrowska, Walentyna Balwierz, et al. · Targeted Oncology · 15
PDF
Role of HMOX1 Promoter Genetic Variants in Chemoresistance and Chemotherapy Induced Neutropenia in Children with Acute Lymphoblastic Leukemia
2021 · Karolina Bukowska-Strakova, Joanna Włodek, et al. · International Journal of Molecular Sciences · 14
PDF
New method for quantitative analysis of GD2 ganglioside in plasma of neuroblastoma patients.
2009 · Dominik Czaplicki, Irena Horwacik, et al. · Acta Biochimica Polonica · 12
PDF
Factors Modifying Outcome After MIBG Therapy in Children With Neuroblastoma—A National Retrospective Study
2021 · Marek Ussowicz, Aleksandra Wieczorek, et al. · Frontiers in Oncology · 11
PDF
Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
2023 · Holger N. Lode, Ruth Ladenstein, et al. · Cancers · 10
PDF
Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: experience of the Polish Paediatric Solid Tumours Study Group
2022 · Aleksandra Wieczorek, Joanna Stefanowicz, et al. · BMC Cancer · 9
PDF
[Treatment results of children with neuroblastoma: report of Polish Pediatric Solid Tumor Group].
2010 · Walentyna Balwierz, Aleksandra Wieczorek, et al. · PubMed · 9
Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma
2024 · Agata Marjańska, Katarzyna Pawińska-Wąsikowska, et al. · Cancers · 6
PDF
Pediatric Hematology and Oncology Center Integrated by Telemedicine: Experience, Challenges and First Results of a Cross Border Network
2023 · Tabea Troschke, Aleksandra Wieczorek, et al. · Healthcare · 5
PDF
Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison
2025 · Holger N. Lode, Przemysław Holko, et al. · Cancers · 4
PDF
Concentrations of adipokines in children before and after hematopoietic stem cell transplantation
2016 · Szymon Skoczen, Przemyslaw J. Tomasik, et al. · Pediatric Hematology and Oncology · 4
Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children—the Polish Pediatric Leukemia and Lymphoma Study Group experience
2023 · Katarzyna Pawinska-Wasikowska, Malgorzata Czogala, et al. · Frontiers in Immunology · 3
PDF
Works count: 56
Citation count: 500
H-index: 14
I10-index: 18
Year
Topic
Type